company background image
GMT logo

Genomtec WSE:GMT Stock Report

Last Price

zł11.80

Market Cap

zł144.6m

7D

11.8%

1Y

14.8%

Updated

25 Mar, 2024

Data

Company Financials

GMT Stock Overview

Genomtec S.A. researches, develops, manufactures, and commercializes innovative molecular diagnostic products in optical systems and isothermal nucleic acid amplification methods in Poland and internationally.

GMT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Genomtec S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Genomtec
Historical stock prices
Current Share Pricezł11.80
52 Week Highzł14.00
52 Week Lowzł8.14
Beta0.44
1 Month Change17.41%
3 Month Change12.92%
1 Year Change14.79%
3 Year Change-28.92%
5 Year Changen/a
Change since IPO-12.92%

Recent News & Updates

Is Genomtec (WSE:GMT) In A Good Position To Deliver On Growth Plans?

May 09
Is Genomtec (WSE:GMT) In A Good Position To Deliver On Growth Plans?

Recent updates

Is Genomtec (WSE:GMT) In A Good Position To Deliver On Growth Plans?

May 09
Is Genomtec (WSE:GMT) In A Good Position To Deliver On Growth Plans?

Shareholder Returns

GMTPL BiotechsPL Market
7D11.8%-2.2%1.5%
1Y14.8%-15.8%36.2%

Return vs Industry: GMT exceeded the Polish Biotechs industry which returned -15.8% over the past year.

Return vs Market: GMT underperformed the Polish Market which returned 36.2% over the past year.

Price Volatility

Is GMT's price volatile compared to industry and market?
GMT volatility
GMT Average Weekly Movement5.7%
Biotechs Industry Average Movement4.8%
Market Average Movement4.9%
10% most volatile stocks in PL Market9.5%
10% least volatile stocks in PL Market3.3%

Stable Share Price: GMT has not had significant price volatility in the past 3 months.

Volatility Over Time: GMT's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201614Miron Tokarskihttps://www.genomtec.com

Genomtec S.A. researches, develops, manufactures, and commercializes innovative molecular diagnostic products in optical systems and isothermal nucleic acid amplification methods in Poland and internationally. The company develops Genomtec ID, a technological device that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analyzing the biological material of patients using swabs, urine samples, saliva, blood, and other body fluids. It also develops Genomtec Tumor, a SNAAT based solution used to identify neoplastic mutations and mutations with prognostic value in neoplastic disease; Genomtec SARS-CoV-2 EvaGreen and Direct-RT-LAMP CE-IVD Kit to detect SARS-CoV-2 RNA in various biological samples from patients with suspected COVID-19 infection; and Genomtec RT-LAMP CE-IVD Duo-Kit for the detection of all variants of the SARS-CoV-2 virus.

Genomtec S.A. Fundamentals Summary

How do Genomtec's earnings and revenue compare to its market cap?
GMT fundamental statistics
Market capzł144.64m
Earnings (TTM)-zł13.35m
Revenue (TTM)zł19.00k

7,613x

P/S Ratio

-10.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GMT income statement (TTM)
Revenuezł19.00k
Cost of Revenuezł2.47m
Gross Profit-zł2.45m
Other Expenseszł10.90m
Earnings-zł13.35m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Apr 25, 2024

Earnings per share (EPS)-1.09
Gross Margin-12,884.21%
Net Profit Margin-70,252.63%
Debt/Equity Ratio3.7%

How did GMT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.